Final Version PATENT TRANSFER AGREEMENT

Exhibit 10.2

THIS AGREEMENT is made as of May 11, 2005 by and between Schering Aktiengesellschaft, a German corporation having its principal place of business at Xxxxxxxxxxxx 000, 00000 Xxxxxx, Xxxxxxx (hereinafter referred to as “Schering”) and Acusphere, Inc., a Delaware corporation having its place of business at 000 Xxxxxxx Xxxxxx, Xxxxxxxxx, XX 00000, XXX (hereinafter referred to as “Acusphere”). Schering and Acusphere are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

WITNESSETH:

WHEREAS, on December 16, 2004 Schering and Acusphere have entered into a Confidentiality Agreement with respect to information regarding ultrasound contrast agents and related patents and patent applications;

WHEREAS, Acusphere indicated its interest in acquiring the Ultrasound Patents (hereinafter defined);

WHEREAS, Schering and Acusphere have previously entered into a non-binding term sheet (the “Term Sheet”) regarding the acquisition of the Ultrasound Patents by Acusphere and wish to incorporate the terms and conditions of such Term Sheet in more detail in a binding agreement.

NOW, THEREFORE, the Parties hereby agree as follows:

Article I - Definitions

“Affiliate” shall mean, with respect to a Party, any person, corporation, firm, joint venture, or other entity which, directly or indirectly, by itself or through one or more intermediaries, controls, is controlled by, or is under common control with such Party. As used in this definition, the term “control” shall mean the possession of the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of at least 50 % of the outstanding voting securities or by contract or otherwise.

“Business Day” shall mean a day which is not a Saturday, a Sunday or other day on which banks are required or authorized by law to be closed in the United States, or in Berlin, Germany.

“Confidential Information” shall have the meaning set forth in Section 4.1.

“Effective Date” shall mean the date first written above.

“Harmonic Imaging Patents” shall mean all world-wide pending patent applications and all patents in the field of harmonic imaging as listed in Appendix C, including any continuation, continuation-in-part, divisional, provisional or any substitute application, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplemental patent certificate or certificate of protection) of any such patent, and all foreign counterparts existing at the Effective Date which are the subject matter of the claims of any of the foregoing.

“Losses” shall have the meaning set forth in Section 6.1.

“Third Party” shall mean any entity other than Acusphere or Schering or their respective Affiliates.

“Third Party Rights” shall mean the contracts and agreements relating to the Ultrasound Patents or Ultrasound Trademarks as listed in Appendix B.

“Ultrasound Patents” shall mean all world-wide pending patent applications and all patents in the ultrasound field, but not including the Harmonic Imaging Patents, as listed in Appendix A, including any continuation, continuation-in-part, divisional, provisional or any substitute application, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplemental patent certificate or certificate of protection) of any such patent, and all foreign counterparts, and all inventions existing at the Effective Date which are the subject matter of the claims of any of the foregoing.

“Ultrasound Trademarks” shall mean the trademarks EchovistÒ and LevovistÒ.

Article II - Transfer of Ultrasound Patents; License Grant

2.1 As of the Effective Date, Schering hereby sells, assigns and transfers to Acusphere all right, title and interest in and to the Ultrasound Patents, including, but not limited to, all claims for damages already incurred, and the right to xxx for past infringement. Acusphere accepts such transfer and assignment. The Ultrasound Trademarks are not part of the transfer. Neither Schering nor any of its Affiliates owns any trademarks

relating to ultrasound contrast agents other than the Ultrasound Trademarks. For the avoidance of doubt, Schering makes no sale, assignment and/or transfer of any right, title and interest in or to the Third Party Rights. Acusphere accepts no responsibility or liability under or arising out of any Third Party Rights; provided that, Acusphere acknowledges and agrees that the non-exclusive licenses previously granted by Schering in the Third Party Rights to certain of the Ultrasound Patents shall hereafter continue in effect in accordance with the terms and conditions of such Third Party Rights.

2.2 As of the Effective Date and subject to the terms and conditions contained herein, Acusphere hereby grants to Schering and its Affiliates a non-exclusive, royalty-free, worldwide license under the Ultrasound Patent family corresponding to EP 0 365 467 B1 (Schering No. 50111) (the “Licensed Patents”) with the right to sublicense, to use, make or have made, promote, sell and have sold its ultrasound product LevovistÒ; provided that each sublicensee is bound by a written agreement which contains terms and conditions at least as protective of the Licensed Patents as those contained herein. Except for the limited licenses expressly granted in this Section 2.2, Acusphere retains all right, title and interest in and to the Licensed Patents.

2.2.1 Schering agrees to promptly notify Acusphere in writing of any actual or threatened infringement by a third party of any Licensed Patents or of any claim of invalidity or unenforceability of the Licensed Patents. Acusphere shall have the right, but not the obligation, to prosecute or defend such claims, as applicable. Schering shall, if requested by Acusphere, provide reasonable assistance to Acusphere, at Acusphere’s expense, in connection with the prosecution or defense of such claims.

2.3 Schering shall be responsible for the execution, delivery and filing of any and all documents or instruments necessary to vest full title to the Ultrasound Patents in Acusphere. Accordingly, Schering shall, on the Effective Date (or as promptly thereafter as is practicable), provide all declarations and sign, deliver and file all documents (or procure that such documents are signed, delivered and filed) that are necessary for the assignment and transfer of the Ultrasound Patents and/or their re-registration in the name of Acusphere or an Acusphere Affiliate. Acusphere acknowledges that in order to fulfill its obligations hereunder Schering needs prompt information from Acusphere on the name of the Acusphere Affiliate, in which the full title to the Ultrasound Patents shall be vested, if not directly in Acusphere. In addition, Schering needs to promptly know the patent counsel of Acusphere who shall be responsible for the Ultrasound Patents thereafter in the respective countries. Any

costs associated with the assignment and transfer of the Ultrasound Patents shall be borne by Schering.

2.4 Schering irrevocably covenants to Acusphere that it will not and will ensure that none of the Schering Affiliates initiate, assist any third party, or otherwise participate in, except where such participation is required pursuant to a judicial or regulatory order or subpeona, in any claim, proceeding, suit or other similar action to invalidate or otherwise challenge the validity or enforceability of any of the Ultrasound Patents.

2.5 Schering shall have paid any annuity, renewal, or administrative fee related to the Ultrasound Patents that are due on or before the Effective Date. As of the Effective Date, Acusphere shall be responsible for any annuity, renewal or administration fee related to each of the Ultrasound Patents; provided, however, (a) in order to permit Acusphere or an Acusphere Affiliate adequate time to assume full administrative responsibility for the payment of any annuity, renewal or administrative fees due for the Ultrasound Patents after the Effective Date, Schering agrees to arrange to pay any such annuity, renewal or administration fee due on the Ultrasound Patents within ninety (90) days of the Effective Date (or until such time as Acusphere or an Acusphere Affiliate advises Schering, in writing, that it no longer requires the annuity, renewal or administration fees so due), Acusphere or an Acusphere Affiliate to reimburse Schering for any such fees, and (b) Acusphere shall have no obligation to prosecute or maintain any Ultrasound Patent that it determines, in its sole discretion, to abandon or lapse; provided that Acusphere shall give Schering notice of its intention to abandon any of the Licensed Patents and Schering shall have the right, but not the obligation, to assume responsibility for the payment of maintenance fees. Fees already paid by Schering prior to the Effective Date shall neither totally nor partially be charged back to Acusphere in any way.

2.6 Schering shall, on the Effective Date, deliver to Acusphere all copies in its or its counsel’s possession of files relating to the prosecution and defense of all of the Ultrasound Patents, including, without limitation, the entire “file wrapper” (prosecution history) of all issued and pending Ultrasound Patents, including official correspondence (office actions, amendments, etc.) to and from, and notes of telephone conversations with, any U.S. and foreign governmental or regulatory authority regarding all of the Ultrasound Patents. After the Effective Date, Schering is willing to assist Acusphere, to the extent that Schering’s internal resources and capabilities allow, in the filing and prosecution of any patent applications included in the Ultrasound Patents and in the defense of any of the Ultrasound Patents before the U.S. Patent and Trademark Office and equivalent foreign governmental

authorities. Acusphere shall reimburse Schering for the reasonable cost of any such cooperation.

2.7 Schering hereby grants Acusphere and each Acusphere Affiliate an irrevocable (except as otherwise set forth in Section 7.3), non-exclusive, royalty-free, fully paid up, non-sublicenseable, worldwide, perpetual right and license to use the Harmonic Imaging Patents solely in connection with exercising its rights in and to any and all of the Ultrasound Patents or in connection with the manufacture, use, importation, or sale of ultrasound contrast agents owned or controlled by Acusphere, including without limitation, the right and license to develop, have developed, manufacture, have manufactured, market, promote, sell, have sold, offer for sale, have offered for sale, import, have imported, rent, provide and/or lease products or services which practice or embody, or are configured for use in practicing, the Harmonic Imaging Patents and the right to practice any method covered by the Harmonic Imaging Patents.

Article III - Payments; Payment Terms

3.1 In consideration of the assignment and transfer of the Ultrasound Patents, Acusphere shall pay to Schering an overall amount of $7,000,000 (seven million USD) to be paid in the following installments:

• $ 1,000,000.00 (one million USD) within 15 Business Days of the Effective Date of this Agreement;

• $ 3,000,000.00 (three million USD) within 15 Business Days of the first anniversary of the Effective Date of this Agreement;

• $ 3,000,000.00 (three million USD) within 15 Business Days of the second anniversary of the Effective Date of this Agreement.

All payments are due as listed above without invoice and shall be made to a bank account to be notified by Schering in due time. For any delayed payment Schering has the right to charge computed interest to Acusphere at Prime Rate as quoted on internet page ‘xxxx://xxx.xxxxxxxxxxxxx.xxx/xxxxx/xxxxx.xxx?Xxxx_Xxxxxxxxxxxxx’”plus a premium of 3% p.a. computed on the basis of act/360 year, such interest to be due and payable upon tender of the payment.

Article IV – Confidentiality; Public Announcements

4.1 Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that the receiving Party shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any Confidential Information of the other Party. As used herein, “Confidential Information” means any information and materials other than the Ultrasound Patents or Harmonic Imaging Patents furnished to a Party by the other Party pursuant to this Agreement that (a) the disclosing Party has marked as confidential or proprietary, or (b) the disclosing Party identifies as confidential at the time of oral disclosure with written confirmation within 15 days of disclosure to the receiving Party; provided, that the provisions of this Agreement will be deemed Confidential Information of both Parties; provided, further however, that reports and/or information related to or regarding the disclosing Party’s business plans, business methodologies, strategies, technology, specifications, development plans, customers, prospective customers, billing records, and products or services will be deemed Confidential Information of the disclosing Party even if not so marked or identified, except to the extent that it can be established by the receiving Party that such Confidential Information:

(a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party, as evidenced by written records maintained by the receiving Party in the ordinary course of business; or

(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; or

(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; or

(d) was disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others.

4.2 Each Party may disclose Confidential Information hereunder to the extent such disclosure is reasonably necessary to comply with applicable governmental laws, rules and regulations, including, without limitation, those of the U.S. Food and Drug Administration (“FDA”) and Securities and Exchange Commission. If a Party is required by law or regulation to make any such disclosure of the other Party’s Confidential Information it will give reasonable advance notice to the other Party of

such disclosure requirement and shall permit the other Party to intervene therein to protect its interests in its Confidential Information, and provide full cooperation and assistance to other Party in seeking to obtain such protection; provided, however, that none of the rights and obligations set forth in this sentence shall apply to any such disclosure by Acusphere in a Form 8-K or Form 10-Q which is filed with the Securities and Exchange Commission within 45 days of the Effective Date.

4.3 Notwithstanding any of the foregoing to the contrary, Acusphere may prepare and issue a press release announcing and describing this Agreement and the transaction contemplated hereby. At least 5 (five) Business Days prior to releasing such press release, Acusphere shall give Schering the opportunity to review and comment thereon. Acusphere shall refer to Schering in such release as “Schering AG, Germany”.

4.4 Except as set forth in Section 4.3, neither Party shall use the name of the other Party or any Affiliate of the other Party in relation to this Agreement or the transactions described herein in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld, conditioned or delayed; provided, however, that either Party may use the name of the other Party in any document filed with any regulatory agency or authority to comply with legal or regulatory requirements, including the FDA and the Securities and Exchange Commission, in which cases Acusphere shall refer to Schering as “Schering AG, Germany”. Notwithstanding the foregoing, Schering agrees not to disclose the terms of this Agreement to its sublicensees within 90 days after the Effective Date.

4.5 This Article IV shall survive termination or expiration of this Agreement.

Article V - Representations and Warranties; Limitation

5.1 Each of the Parties represents and warrants to the other Party that (a) it has full right, power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby, (b) this Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms, and (c) the execution, delivery and performance of the Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it is bound, nor to such Party’s knowledge, violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.

5.2 Schering hereby represents and warrants to Acusphere that

(a) Schering is the rightful and exclusive owner of all right, title and interest in and to the Ultrasound Patents;

(b) the Ultrasound Patents are free and clear of any liens, license rights, security interests, encumbrances or rights to repurchase, other than those listed in Appendix B;

(c) each of the Ultrasound Patents is properly filed or issued, as applicable, currently in compliance with formal legal requirements (including, without limitation, payment of filing, examination and governmental taxes and maintenance fees) and enforceable and, to the knowledge of Schering or any of its Affiliates, valid.

(d) there are no pending, or, to the knowledge of Schering or any of its Affiliates, threatened claims against Schering or any of its Affiliates claiming that the making, using, selling, offering for sale or importing of products or services which are covered by the subject matter of the claims of the Ultrasound Patents infringe on or violate any patent or other intellectual property right of a person or entity or that any of the Ultrasound Patents is invalid or unenforceable and Schering is not aware of any facts or circumstances that would form the basis for a determination that any of such Ultrasound Patents are invalid or unenforceable.

(e) to the knowledge of Schering or any of its Affiliates, the making, using, selling, offering for sale or importing of products or services which are covered by the subject matter of the claims of the Ultrasound Patents does not infringe on or violate (or in the past did not infringe on or violate) any patent or other intellectual property right of a person or entity.

(f) to the knowledge of Schering or any of its Affiliates, there is no, nor has there been any, infringement or violation or alleged infringement or violation by any person or entity of any of Schering’s rights in or to the Ultrasound Patents.

(g) All licenses or other agreements under which Schering has granted rights to others in the Ultrasound Patents are listed in Appendix B attached hereto. All such licenses or other agreements are in full force and effect, and, to the

knowledge of Schering there is no material default by any Party thereto. True and complete copies of all such licenses or other agreements, and any amendments thereto, have been provided to Acusphere with certain limited redactions thereto, and Schering has all requisite power and authority to grant the rights purported to be conferred thereby.

(h) Appendix A comprises a complete and accurate listing of all patents and patent applications owned or controlled by Schering or any Affiliate of Schering in the ultrasound field; and Appendix C comprises a complete and accurate listing of all Harmonic Imaging Patents owned or controlled by Schering or any Affiliate of Schering.

5.3 EXCEPT AS SET FORTH ABOVE IN SECTION 5.2, EACH PARTY MAKES NO AND DISCLAIMS ANY OTHER WARRANTY OR REPRESENTATION, EXPRESS OR IMPLIED, CONCERNING THE ULTRASOUND PATENTS, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE,

Article VI - Indemnification

6.1 Without prejudice to any other right or remedy available to either Party arising out of the breach by the other of any of the representations and warranties set out in Sections 5.1 and 5.2 above, each Party hereby agrees to indemnify, defend and hold the other Party and its Affiliates, directors, officers, and employees harmless from and against any and all suits, claims, actions, demands, liabilities, expenses and/or losses, including reasonable legal expenses and attorneys’ fees (collectively, “Losses” and each a “Loss”), resulting directly or indirectly from (i) the material breach of any obligation under this Agreement, or (ii) the material breach of any representation or warranty made by such Party hereunder; provided however that neither party shall indemnify the other party for loss of profit.

6.2 Each indemnified Party agrees to give the indemnifying Party prompt written notice of any Loss or discovery of fact upon which such indemnified Party intends to base a request for indemnification under Section 6.1. Each Party shall furnish promptly to the other copies of all papers and official documents received in respect of any Loss. The indemnifying Party shall have the sole right to defend, settle or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall deem appropriate. The indemnifying Party shall obtain the written consent of the indemnified Party, which shall not be unreasonably withheld or delayed, prior to

ceasing to defend, settling or otherwise disposing of any Loss if as a result thereof the indemnified Party would become subject to injunctive or other equitable relief or any remedy other than the payment of money, which payment would be the responsibility of the indemnifying Party. The indemnifying Party shall not be liable for any settlement or other disposition of a Loss by the indemnified Party which is reached without the written consent of the indemnifying Party. The reasonable costs and expenses, including reasonable fees and disbursements of counsel incurred by any indemnified Party in connection with any Loss, shall be reimbursed on a quarterly basis by the indemnifying Party, without prejudice to the indemnifying Party’s right to contest the indemnified Party’s right to indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the indemnified Party.

6.3 This Article VI shall survive the termination or expiration of this Agreement.

Article VII - Term and Termination

7.1 This Agreement shall come into force on the Effective Date and shall continue in effect until the last Ultrasound Patent licensed back to Schering under Section 2.2 has expired.

7.2 In case that Schering or any of its Affiliates or sublicensees of Schering or any of Schering’s Affiliates attempts to challenge the validity or enforceability of the Licensed Patents, Acusphere has the right to immediately terminate the license granted in Section 2.2 above upon written notice.

7.3 In the event that Acusphere acquires (whether through a purchase of assets or stock, merger or otherwise) a Third Party which, immediately prior to the closing of such acquisition, is a party to an effective agreement under which Schering has granted such Third Party a royalty bearing license under any of the Harmonic Imaging Patents (any such agreement, a “Harmonic Imaging Patent License”), Acusphere shall promptly notify Schering of such acquisition. Thereafter, upon Schering’s written request, the parties shall amend this Agreement to clarify that the Harmonic Imaging Patent License royalty obligations with respect to the Harmonic Imaging Patents covered therein supercede the royalty free license granted in Section 2.7 above and confirm that Acusphere and/or an Acusphere Affiliate, as applicable, shall pay all royalties set forth in and subject to the terms and conditions of the Harmonic Imaging Patent License with respect to those Harmonic Imaging Patents covered therein.

7.4 The rights and obligations set forth in this Agreement shall extend beyond the expiration of this Agreement only to the extent expressly provided for herein, or to the extent that the survival of such rights or obligations are necessary to permit their complete fulfillment or discharge

Article VIII - Miscellaneous

8.1 Amendments. No subsequent amendment or addition to this Agreement shall be binding upon the Parties unless executed in writing and signed by the respective authorized representatives of the Parties.

8.2 Headings. The section and paragraph headings contained herein are for the purposes of convenience only and are not intended to define or limit the contents of said sections or paragraphs.

8.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement.

8.4 Severability. Each Party hereby agrees that it does not intend, by its execution hereof, to violate any public policies, statutory or common laws, rules, regulations, treaties or decisions of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become invalid, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid provisions, which valid provisions in their economic and other effects are sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the invalidity of one or several provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid provision.

8.5 Prior Agreements. This Agreement constitutes the full and entire understanding and agreement among the Parties hereto with respect to the subject matters hereof, and any and all other written or oral agreements existing prior to or contemporaneously herewith, including but not limited to, the Term Sheet between the Parties, are hereby expressly superseded by the provisions of this Agreement. The Confidentiality Agreement dated December 16, 2004 shall continue to apply.

8.6 Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given when delivered personally or when mailed, by certified or registered mail, prepaid, to the Parties or their assignees at the address set forth above (or at such other address as shall be given in writing by a Party).

8.7 Governing Law and Dispute Resolution.

This Agreement shall be governed by and construed in accordance with the laws of Germany. All disputes arising in connection with this Agreement or its validity which cannot be resolved amicably by the Parties shall be finally settled according to the rules of the German Institution of Arbitration e.V. (Deutsches Institut für Schiedsgerichtsbarkeit e.V.) without recourse to the ordinary courts of law except for interim proceedings (einstweiliger Rechtschutz). The exclusive place of arbitration shall be Frankfurt am Main, Germany. The arbitral tribunal shall consist of three arbitrators, one arbitrator to be appointed by each Party and the third to be appointed by the Arbitration Institution. The language of the arbitral proceedings shall be English.

IN WITNESS WHEREOF, Schering and Acusphere have caused this Agreement to be executed as of the Effective Date by their respective duly authorized representatives.

Acusphere, Inc.	Schering Aktiengesellschaft

/s/ Xxxxxx X. Xxxxx	/s/ X.X. Xxxx
Name: Xxxxxx X. Xxxxx	Name: X.X. Xxxx
Title: President and CEO	Title: Head of GBU Diagnostic Imaging


	/s/ Xx. X. Xxxxxxxx
	Name: Xx. X. Xxxxxxxx
	Title:	Business Development Diagnostic
	Imaging, Licensing & Cooperations

Appendix A - Ultrasound Patents

Patent Family # 03228A

Ctry

Type

Filing

Filing
Number

Publication

Xxxxx

Xxxxx
number

Proc

Date

Nature

Exp

NP1

05/Feb/1988

P 3803972.9

10/Aug/1989

04/Jul/0000

0000000

GRT

04/Jul/1989

3803972

05/Feb/2008

PCT1

01/Feb/1989

1864/90

NATF

03/Aug/1990

1864/90

01/Feb/2009

CNT2

11/Jun/1990

07/536377

FLG

11/Jun/1990

07/536377

CNT3

07/Jun/1993

08/072748

20/Jun/0000

0000000

GRT

20/Jun/1995

5425366

20/Jun/2012

CNT4

13/Feb/1995

08/387612

FLG

13/Feb/1995

08/387612

CNT5

07/Jun/1995

08/477642

06/Jun/2000

6071496

GRT

06/Jun/2000

6071496

06/Jun/2017

CNT6

07/Jun/1995

08/474468

23/Jan/2001

6177062 B1

GRT

23/Jan/2001

6177062 B1

06/Jun/2017

CNT7

29/Nov/1995

08/563926

FLG

29/Nov/1995

08/563926

03/Feb/2009

CNT8

24/Feb/2000

09/512473

FLG

24/Feb/2000

09/512473

03/Feb/2009

A-1

Patent Family # 50111A

Ctry

Type

Filing

Filing Number

Publication

Xxxxx

Xxxxx
number

Proc

Date

Nature

Exp

EPA1

06/Apr/1989

89730095.0

25/Apr/1990

18/Aug/1993

P 58905318.3-08

GRT

18/Aug/1993

P 58905318.3-08

06/Apr/2009

SPC1

07/Jun/1996

19675015.6

13/Dec/1995

32851.00.00

GRT

13/Dec/1995

32851.00.00

21/Jun/2010

EPA1

06/Apr/1989

89730095.0

25/Apr/1990

18/Aug/0000

0000000

GRT

18/Aug/1993

0365467

06/Apr/2009

SPC1

29/Jan/1998

C 9800006

01/Sep/1999

C 9800006

XXX

00/Xxx/0000

X 0000000

00/Xxx/0000

XXX0

06/Apr/1989

89730095.0

25/Apr/1990

18/Aug/0000

0000000

GRT

18/Aug/1993

0365467

06/Apr/2009

SPC1

06/Apr/1989

89730095.0

10/Oct/1999

97 C 0000

XXX

10/Oct/1999

97 C 0008

20/Jun/2010

XXX0

06/Apr/1989

89730095.0

25/Apr/1990

18/Aug/0000

0000000

GRT

18/Aug/1993

0365467

06/Apr/2009

SPC1

22/Nov/1996

SPC/GB96/055

21/Apr/1997

SPC/GB96/055

GRT

21/Apr/1997

SPC/GB96/055

20/Jun/2010

EPA1

06/Apr/1989

89730095.0

25/Apr/1990

18/Aug/0000

0000000

GRT

18/Aug/1993

0365467

06/Apr/2009

SPC1

30/Oct/1996

FLG

30/Oct/1996

06/Apr/2014

NP1

04/Oct/1989

258007/89

11/Jan/0000

0000000

XXX

00/Xxx/0000

0000000

00/Xxx/0000

SPC1

03/Sep/1999

11-700082

22/Feb/2001

2005630

GRT

22/Feb/2001

2005630

04/Oct/2014

A-2

Patent Family # 50622A

Ctry

Type

Filing

Filling
Number

Publication

Xxxxx

Xxxxx
number

Proc

Date

Nature

Exp

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/1998

E 163134

GRT

11/Feb/1998

E 163134

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/1998

59308146.3-08

GRT

11/Feb/1998

59308146.3-08

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

00/Xxx/0000

EPT1

02/Jun/1993

20040400095

29/Mar/1995

11/Feb/0000

0000000.B2

GRT

11/Feb/0000

0000000.B2

02/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

PCT1

05/Jun/1993

19944805

08/May/2000

307646

XXX

00/Xxx/0000

000000

00/Xxx/0000

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000

GRT

11/Feb/1998

0644777

05/Jun/2013

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/1998

93912897-1

GRT

11/Feb/1998

93912897-1

05/Jun/2013

PCT1

05/Jun/1993

08/351372

NATF

13/Dec/1994

08/351372

EPT1

05/Jun/1993

93912897.1

29/Mar/1995

11/Feb/0000

0000000/E78869

GRT

11/Feb/0000

0000000/E78869

05/Jun/2013

A-3

Patent Family # 50686A

Ctry

Type

Filing

Filing
Number

Publication

Xxxxx

Xxxxx
number

Proc

Date

Nature

Exp

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/1998

E 173937

GRT

02/Dec/1998

E 173937

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

PCT1

24/Apr/1993

2137910

03/Jun/2003

2137910

XXX

00/Xxx/0000

0000000

00/Xxx/0000

XXX0

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/1998

59309189.2-08

GRT

02/Dec/1998

59309189.2-08

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

XXX

00/Xxx/0000

0000000

00/Xxx/0000

XXX0

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/1998

990400590/3029494

GRT

02/Dec/1998

990400590/3029494

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

PCT1

24/Apr/1993

944806

25/Sep/2000

308510

GRT

25/Sep/2000

308510

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/0000

0000000

GRT

02/Dec/1998

0644776

24/Apr/2013

EPT1

24/Apr/1993

93911501.0

29/Mar/1995

02/Dec/1998

93911501-0

GRT

02/Dec/1998

93911501-0

24/Apr/2013

A-4

Patent Family #50716A

Ctry

Type

Filing

Filing Number

Publication

Xxxxx

Xxxxx
number

Proc

Date

Nature

Exp

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/1998

E 165517

GRT

29/Apr/1998

E 165517

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

PCT1

08/Sep/1993

2145505

17/Feb/2004

CA 2145505

GRT

17/Feb/2004

CA 2145505

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

NP1

25/Sep/1993

93118159.3

20/Jul/1994

06/Feb/2002

00000

XXX

06/Feb/2002

80509

25/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/1998

59308479.9-08

GRT

29/Apr/1998

59308479.9-08

08/Sep/2013

NP1

26/Sep/1992

P 4232755.5

31/Mar/1994

PUB

31/Mar/1994

DE 4232755 A1

26/Sep/2012

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

PCT1

08/Sep/1993

951379

NATF

23/Mar/1995

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/1998

980401268/3027050

GRT

29/Apr/1998

980401268/3027050

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

29/Apr/0000

0000000/E 80081

GRT

29/Apr/0000

0000000/E 80081

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

PCT1

08/Sep/1993

19951138

15/May/2000

307692

GRT

15/May/2000

307692

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/0000

0000000

GRT

29/Apr/1998

0662005

08/Sep/2013

EPT1

08/Sep/1993

93919293.6

12/Jul/1995

29/Apr/1998

93919293.6

GRT

29/Apr/1998

93919293.6

08/Sep/2013

CWO1

21/Jul/1997

08/897319

07/Mar/2002

07/May/2002

6383470 B1

GRT

07/May/2002

6383470 B1

08/Sep/2013

PCT1

08/Sep/1993

08/406882

NATF

27/Mar/1995

08/406882

A-5

Patent Family #50902A

Ctry

Type

Filing

Filing
Number

Publication

Xxxxx

Xxxxx
number

Proc

Date

Nature

Exp

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

PCT1

25/Aug/0000

0000000

FLG

25/Aug/1994

2171303

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

59409568.9-08

GRT

25/Oct/2000

59409568.9-08

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

20010400035/3035219

GRT

25/Oct/2000

20010400035/3035219

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

PCT1

25/Aug/1994

960973

04/Mar/2002

312007

GRT

04/Mar/2002

312007

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

0717617

GRT

25/Oct/2000

0717617

25/Aug/2014

EPT1

25/Aug/1994

94926878.3

26/Jun/1996

25/Oct/2000

94926878.3

GRT

25/Oct/2000

94926878.3

25/Aug/2014

DWO1

13/Dec/1999

09/459578

04/Sep/2001

6284280 B1

GRT

04/Sep/2001

6284280 B1

25/Aug/2014

PCT1

25/Aug/1994

08/605174

30/May/2000

6068857

GRT

30/May/2000

6068857

30/May/2017

A-6

Patent family # 51090A

Ctry

Type

Filing

Filing
Number

Publication

Xxxxx

Xxxxx
number

Proc

Date

Nature

Exp

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

GRT

19/Sep/2001

0744961

10/Feb/2015

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

XXX

00/Xxx/0000

0000000

00/Xxx/0000

XXX0

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

GRT

19/Sep/2001

0744961

10/Feb/2015

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

59509618.2-08

GRT

19/Sep/2001

59509618.2-08

10/Feb/2015

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

GRT

19/Sep/2001

0744961

10/Feb/2015

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

GRT

19/Sep/2001

0744961

10/Feb/2015

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

GRT

19/Sep/2001

0744961

10/Feb/2015

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

GRT

19/Sep/2001

0744961

10/Feb/2015

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

GRT

19/Sep/2001

0744961

10/Feb/2015

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

XXX

00/Xxx/0000

0000000

00/Xxx/0000

PCT1

10/Feb/1995

07-522099

FLG

10/Feb/1995

07-522099

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

GRT

19/Sep/2001

0744961

10/Feb/2015

PCT1

10/Feb/1995

19963501

21/May/2002

312497

GRT

21/May/2002

312497

10/Feb/2015

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

0744961

GRT

19/Sep/2001

0744961

10/Feb/2015

EPT1

10/Feb/1995

95909702.3

04/Dec/1996

19/Sep/2001

95909702.3

GRT

19/Sep/2001

95909702.3

10/Feb/2015

DWO1

06/Aug/1998

09/129953

23/Oct/2001

6306366 B1

GRT

23/Oct/2001

6306366 B1

10/Feb/2015

PCT1

10/Feb/1995

08/700354

NATF

21/Oct/1996

08/700354

A-7

Patent Family #51639A

Ctry

Type

Filing

Filing Number

Publication

Xxxxx

Xxxxx
number

Proc

Date

Nature

Exp

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

PCT1

23/May/2000

59627/00

08/Sep/2003

05/Feb/2004

766705

GRT

05/Feb/2004

766705

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

PCT1

23/May/2000

2373869

NATF

13/Nov/2001

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

PCT1

23/May/2000

00811021.2

NATF

27/Nov/2001

00811021.2

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

PCT1

23/May/2000

PV 2001-4235

17/Apr/2002

PUB

17/Apr/2002

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

50002914.8-08

GRT

16/Jul/2003

50002914.8-08

23/May/2020

NP1

27/May/1999

19925311.0

30/Nov/2000

15/Jan/2004

19925311.0-09

GRT

15/Jan/2004

19925311.0-09

27/May/2019

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

20030404214

GRT

16/Jul/2003

20030404214

23/May/2020

FPR1

23/May/2000

03102710.2

27/Jun/2003

PUB

27/Jun/2003

1050492 A

23/May/2020

PCT1

23/May/2000

P 0201640

28/Aug/2002

PUB

28/Aug/2002

P 0201640

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

PCT1

23/May/2000

PA/A/2001/011998

NATF

23/Nov/2001

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

PCT1

23/May/2000

20015745

NATF

26/Nov/2001

23/May/2020

PCT1

23/May/2000

515147

25/Jul/2003

03/Nov/2003

515147

GRT

03/Nov/2003

515147

23/May/2020

PCT1

23/May/2000

P-351853

NATF

26/Nov/2001

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

EPT1

23/May/2000

PCT/DE00/01678

20/Feb/2002

16/Jul/2003

1180043

GRT

16/Jul/2003

1180043

23/May/2020

A-8

PCT1

23/May/2000

PV 1691-2001

04/Apr/2002

PUB

04/Apr/2002

23/May/2020

PCT1

23/May/2000

09/979554

25/Nov/2003

6652782 B1

GRT

25/Nov/2003

6652782 X0

00/Xxx/0000

PCT1

23/May/2000

2001/10482

25/Jun/2003

2001/10482

GRT

25/Jun/2003

2001/10482

23/May/2020

A-9

Patent Family #52235A

Ctry

Type

Filing

Filing Number

Publication

Xxxxx

Xxxxx
number

Proc

Date

Nature

Exp

NP1

28/Mar/2002

10215335.3

16/Oct/2003

PUB

16/Oct/2003

DE 10215335 A1

28/Mar/2022

EPT

27/Mar/2003

03745194.5

22/Dec/2004

PUB

22/Dec/2004

1487345

27/Mar/2023

PCT

27/Mar/2003

2003-579664

NATF

28/Sep/2004

2003-579664

27/Mar/2023

NP1

28/Mar/2003

10/400928

13/May/2004

PUB

13/May/2004

US-2004-0092820-A1

28/Mar/2023

PCT

27/Mar/2003

PCT/EP03/03227

FLG

27/Mar/2003

PCT/EP03/03227

A-10

Appendix B
Third Party Rights under Ultrasound Patents; Other Exceptions

1.) Non-exclusive, royalty-free, worldwide license under Ultrasound Patent EP 644 776 was granted to Nycomed Imaging AS (now Amersham Health AS) (“Nycomed”) with the right to sublicense to Affiliates under Settlement Agreement dated as of November 2, 1999 between Schering and Nycomed.

2.) Non-exclusive license under Ultrasound Patent EP 0744961 B1 was granted to Amersham Health AS (“Amersham”) under Settlement and License Agreement dated as of October 8, 2004 between Schering and Amersham.

3.) Non-exclusive royalty free license under Ultrasound Patent EP 644777 was granted to Xxxxxx S.p.A. (“Xxxxxx”) under Letter of Understanding dated as of November 14, 2000 between Schering and Xxxxxx.

X-0

Appendix C
Harmonic Imaging Patents

Patent Family #51172A1

51172

Licenses List

Ctry

Type

Filing

Filing Number

Publication

Xxxxx

Xxxxx Number

Proc

Date

Nature

Exp

PCT1

13/Oct/1995

38424/95

29/Oct/1998

11/Feb/1999

698398

GRT

11/Feb/1999

698398

13/Oct/2015

PCT1

13/Oct/1995

95195991.3

23/Jun/2004

159753

GRT

23/Jun/2004

159753

13/Oct/2015

NP1

31/Oct/1995

115832

24/Aug/1997

08/Mar/1999

115832

XXX

00/Xxx/0000

000000

00/Xxx/0000

PCT1

13/Oct/1995

10-1997-702870

01/Dec/1997

01/Apr/2003

380126

XXX

00/Xxx/0000

000000

00/Xxx/0000

PCT1

13/Oct/1995

972842

18/Aug/2000

198166

GRT

18/Aug/2000

198166

13/Oct/2015

PCT1

13/Oct/1995

972029

NATF

30/Apr/1997

13/Oct/2015

PCT1

13/Oct/1995

295149

28/Oct/1998

10/Feb/1999

295149

GRT

10/Feb/1999

295149

13/Oct/2015

NP1

30/Nov/1995

84112793

21/Oct/1997

11/Feb/1998

NI-090114

GRT

11/Feb/1998

NI-090114

30/Nov/2015

NP1

01/Nov/1994

08/332746

21/Oct/0000

0000000

GRT

21/Oct/1997

5678553

01/Nov/2014

NP1

31/Oct/1995

95/9217

31/Jul/1996

95/9217

GRT

31/Jul/1996

95/9217

31/Oct/2015

C-1

Patent Family #50107

50107

Licenses List

Ctry

Type

Filing

Filing Number

Publication

Xxxxx

Xxxxx Number

Proc

Date

Nature

Exp

EPA1

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/1991

E 00000

XXX

23/Oct/1991

E 68887

23/Aug/2009

PCT1

23/Aug/1989

41824/89

20/May/1993

13/Sep/1993

637059

GRT

13/Sep/1993

637059

23/Aug/2009

EPA1

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/0000

0000000

GRT

23/Oct/1991

0357164

23/Aug/2009

NP1

31/Aug/1989

610016

19/Mar/1996

1338175

GRT

19/Mar/1996

1338175

19/Mar/2013

EPA1

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/0000

0000000

GRT

23/Oct/1991

0357164

23/Aug/2009

EPA1

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/1991

P 58900401.8

GRT

23/Oct/1991

P 58900401.8

23/Aug/2009

PCT1

23/Aug/1989

316/91

02/Jul/1993

00/Xxx/0000

XX 000000

XXX

00/Xxx/0000

XX 000000

23/Aug/2009

EPA1

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/0000

0000000

GRT

23/Oct/1991

0357164

23/Aug/2009

EPA1

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/0000

0000000

GRT

23/Oct/1991

0357164

23/Aug/2009

XXX0

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/0000

0000000

XXX

00/Xxx/0000

0000000

00/Xxx/0000

XXX0

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/1991

910401550

GRT

23/Oct/1991

910401550

23/Aug/2009

EPA1

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/0000

0000000

GRT

23/Oct/1991

0357164

23/Aug/2009

PCT1

23/Aug/1989

1-508941

25/Jul/0000

0000000

GRT

25/Jul/1997

2677888

23/Aug/2009

PCT1

23/Aug/1989

700928/90

23/Feb/1998

138901

GRT

23/Feb/1998

138901

23/Aug/2009

EPA1

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/0000

0000000

GRT

23/Oct/1991

0357164

23/Aug/2009

EPA1

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/0000

0000000

GRT

23/Oct/1991

0357164

23/Aug/2009

PCT1

23/Aug/1989

910805

FLG

23/Aug/1989

910805

23/Aug/2009

EPA1

23/Aug/1989

89250017.4

07/Mar/1990

23/Oct/1991

89250017.4

GRT

23/Oct/1991

89250017.4

23/Aug/2009

NP1

23/Oct/1989

78108117

01/Jan/1992

14/Dec/1991

NI-53209

GRT

14/Dec/1991

NI-53209

23/Oct/2009

CWO1

14/Jun/1993

076221

25/Apr/0000

0000000

GRT

25/Apr/1995

5410516

25/Apr/2012

CWO3

06/Jun/1995

08/467886

16/May/2000

6064628

GRT

16/May/2000

6064628

CWO4

12/Jan/1999

09/228972

07/Mar/2000

6034922

GRT

07/Mar/2000

6034922

23/Aug/2009

CWO5

02/Nov/1999

09/432123

24/Apr/2001

6221017 B1

GRT

24/Apr/2001

6221017 B1

23/Aug/2009

CWO6

20/Dec/2000

09/740054

03/Sep/2002

6443899 B2

GRT

03/Sep/2002

6443899 X0

00/Xxx/0000

NP1

01/Sep/1989

89/6738

27/Jun/1990

89/6738

GRT

27/Jun/1990

89/6738

01/Sep/2009

C-2

Document Metadata

Table of Contents

Final Version PATENT TRANSFER AGREEMENT

Document Metadata